文献速递关节外科

全关节置换术中的万古霉素预防:剂量不当且假体周围感染率高于头孢唑林

Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.
PubMed 文献 · Clin Orthop Relat Res · 2017-01-01

单机构回顾性研究显示,初次全关节置换术中接受万古霉素预防的患者假体周围感染率高于头孢唑林组(2%对1%);仅28%万古霉素给药剂量达标,94%使用固定1克剂量者中64%剂量不足;按体重给药可减少手术开始和结束时万古霉素水平低于15毫克/升的患者比例。

要点

  • 万古霉素组假体周围感染率2%高于头孢唑林组1%,校正比值比1.587(1.004-2.508),p=0.048。
  • 仅28%万古霉素预防患者剂量达标,固定1克剂量者中64%剂量不足。
  • 按体重给药方案较实际固定剂量可减少手术开始和结束时万古霉素水平低于15毫克/升的比例。

核心结论

  • 多数接受万古霉素预防的患者按体重剂量推荐剂量不足,剂量达标患者中未发生耐甲氧西林金黄色葡萄球菌所致假体周围感染。
  • 作者建议外科医生确保患者按15毫克/千克推荐剂量充分给药并及时给药。
  • 基于本研究结果,作者所在机构已趋向于限制择期关节置换术中万古霉素预防的使用。

研究设计与样本

  • 单机构回顾性研究,纳入2008年至2014年间接受初次全关节置换术并接受万古霉素预防的1828例患者,同期5810例接受头孢唑林单药预防。
  • 通过病历回顾获取患者特征、抗生素剂量与给药时机及微生物学数据。
  • 万古霉素剂量达标定义为15毫克/千克且在125毫克范围内,采用药代动力学方程计算手术开始和结束时的万古霉素水平,15毫克/升视为达标。
  • 采用逻辑回归、卡方检验和方差分析进行统计。

主要发现

  • 万古霉素组假体周围感染32/1828(2%),头孢唑林组62/5810(1%),校正比值比1.587(1.004-2.508),p=0.048。
  • 万古霉素剂量不足组假体周围感染中10%(2/20)由耐甲氧西林金黄色葡萄球菌引起,剂量达标或过量组无耐甲氧西林金黄色葡萄球菌所致假体周围感染。
  • 万古霉素单药预防中28%(518/1828)剂量达标,94%(1726/1828)接受固定1克剂量,其中64%(1105/1726)剂量不足。
  • 所有患者万古霉素输注在切皮前2小时内开始。
  • 按体重给药方案较实际固定剂量可减少手术开始时万古霉素水平低于15毫克/升的患者比例(0/1828[0%]对471/1828[26%],比值比0.001[0.000-0.013],p<0.001)及手术结束时(33/1828[2%]对746/1828[41%],比值比0.027[0.019-0.038],p<0.001)。

关键数值与推荐

  • 万古霉素剂量达标定义为15毫克/千克且在125毫克范围内。
  • 万古霉素水平15毫克/升视为达标。
  • 证据等级为III级,治疗性研究。

临床怎么用

  • 作者建议外科医生确保患者按15毫克/千克推荐剂量充分给予万古霉素并及时给药。
  • 基于本研究结果,作者所在机构已趋向于限制择期关节置换术中万古霉素预防的使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In total joint arthroplasty (TJA), vancomycin is used as perioperative antibiotic prophylaxis in patients with penicillin allergy or in patients colonized with methicillin-resistant Staphylococcus aureus (MRSA). Although vancomycin dosing should be weight-based (15 mg/kg), not all surgeons are aware of this; a fixed 1-g dose is instead frequently administered. QUESTIONS/PURPOSES: (1) Is there a difference in the risk of periprosthetic joint infection (PJI) in patients receiving vancomycin or cefazolin prophylaxis after primary TJA? (2) What proportion of patients is adequately dosed with vancomycin? (3) Compared with actual fixed dosing, does weight-based dosing result in a greater proportion of patients staying above the recommended 15-mg/L level at the beginning and end of surgery? (4) Are patients overdosed with vancomycin at greater risk of developing nephrotoxicity and acute kidney injury? METHODS: A single-institution, retrospective study was performed on 1828 patients undergoing primary TJAs who received vancomycin prophylaxis between 2008 and 2014. During the same period, 5810 patients underwent primary TJA and received cefazolin monotherapy. A chart review was performed to obtain patient characteristics, antibiotic dose and timing of administration, and microbiology data. Adequate vancomycin dosing was defined as 15 mg/kg and within the 125-mg range. Vancomycin levels were calculated at the beginning and end of surgery using pharmacokinetic equations. Levels of 15 mg/L were considered adequate. Logistic regression, chi square tests, and analysis of variance were performed. RESULTS: Among primary TJAs, patients receiving vancomycin had a higher rate of PJI (32 of 1828 [2%]) compared with patients receiving cefazolin prophylaxis (62 of 5810 [1%]; adjusted odds ratio, 1.587 [1.004-2.508]; p = 0.048). Ten percent of PJIs in the vancomycin underdosed group (two of 20) was caused by MRSA, and no patients with adequate dosing or overdosing of vancomycin developed PJI with MRSA. Of all procedures in which vancomycin monotherapy was used, 28% (518 of 1828) was adequately dosed according to weight-based dosage recommendations. Furthermore, 94% (1726 of 1828) of patients received a fixed 1-g dose of vancomycin, of whom 64% (1105 of 1726) were underdosed. All patients had vancomycin infusion initiated within 2 hours before incision. A weight-based protocol would have resulted in fewer patients having unacceptably low vancomycin levels (< 15 mg/L) compared with those with actual fixed dosing, both for the beginning of surgery at the time of incision (zero of 1828 [0%] versus 471 of 1828 [26%]; odds ratio, 0.001 [0.000-0.013]; p < 0.001) and at the end of surgery (33 of 1828 [2%] versus 746 of 1828 [41%]; odds ratio, 0.027 [0.019-0.038]; p < 0.001). Between the vancomycin dosage groups, there were no differences in the rate of nephrotoxicity (underdosed: 12 of 1130 [1%], adequately dosed: five of 518 [1%], overdosed: four of 180 [2%], p = 0.363) and acute kidney injury (underdosed: 28 of 1130 [2%], adequately dosed: 10 of 518 [2%], overdosed: six of 180 [3%], p = 0.561). CONCLUSIONS: The majority of patients given vancomycin prophylaxis are underdosed according to the weight-based dosage recommendations, and MRSA did not occur in patients who were adequately dosed with vancomycin. Surgeons should thus ensure that their patients are adequately dosed with vancomycin using the recommendation of 15 mg/kg and that the dose of vancomycin is administered in a timely fashion. Furthermore, and based on the findings of this study, we have moved toward limiting the utilization of vancomycin prophylaxis for patients undergoing elective arthroplasty at our institution. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Kheir MM, Tan TL, Azboy I, et al. Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin. Clin Orthop Relat Res. 2017. PMID: 28401341. doi:10.1007/s11999-017-5302-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。